CD44 and neoplasm: Moreover, activating EGFR in the head and neck CSCs enhanced expressing the genes engaged in the CSC rapid growth or proliferation (OCT4, BMI1, CD44, NANOG) and CSCs treatment through inhibiting EGFR declined the tumor growth and augmented the sensitivity to cisplatin [228].